

URGENT
PRESS RELEASE



Wockhardt Limited
Wockhardt Towers
Bandra Kurla Complex
Bandra (East), Mumbai 400 051, India
Tel.: +91 22 2653 4444 +91 22
2653 4444
Fax: +91 22 2653 4242
Website: www.wockhardt.com

Wockhardt's Q3 (October - December) FY 2011 Results

Wockhardt bounces back with Profits

Consolidated Sales Rs. 950.80 crore

Net Profit Rs. 141.7 crore

Operating Profit grows at 82.0% (EBIDTA Rs. 243.7 crore)

Mumbai, 02 Feb, 2011

Pharmaceutical and Biotechnology major Wockhardt Limited today announced its results for the third quarter ended 31st December 2010. Consolidated Sales revenues stood at Rs. 950.80 crore, showing a 7% growth over the corresponding quarter of 2009. Net Profits stood at Rs. 141.7 crore and operating profit (EBIDTA) was Rs. 243.7 crore, a growth of 82.0%.

"Our operations remain strong and have consistently shown growth in EBIDTA and EBIDTA margins during the current year", said Wockhardt Chairman Dr. Habil Khorakiwala. He further added that EBIDTA has grown by 82.0% and EBIDTA margin is at 25.6%. In this quarter we have shown a net profit of Rs. 141.7 crore.

India Business:

Wockhardt's India branded business grew by 18% in October-December 2010 over the corresponding period of 2009 (IMS). During the said period two new products were launched and overall 8 brands featured amongst the TOP-300 brands of the industry. The generics business grew by 20%, exports (RoW) grew by 30% and Wockhardt's Power Brands grew by 15%.

Europe Business:

Wockhardt UK has crossed sales of £ 100 million in the calendar year of 2010. It is the No.1 Indian generic company with sales revenues growing by 10.2% compared to the industry growth of only 4% during this period. Growth drivers were pharmacy products and exports. Pinewood Healthcare continues to be the No.1 generic company in Ireland, showing exemplary growth of 5% compared to an industry

growth of -2% in the face of an economic downturn and mandatory price reduction by the government. During the quarter, Pinewood launched one new product. Brand Nebilox of Negma Laboratories continues its growth path.

USA Business:

Wockhardt USA clocks a robust 87% growth in the world's most competitive market. 8 new products were introduced in the last 12 months. Currently we have a total of 123 products in the market.

About Wockhardt

Wockhardt is a high technology global pharmaceuticals and biotechnology major with innovative multi-disciplinary research and development programmes. It has 5 research centres and 21 world-class manufacturing plants in India, USA, UK, France and Ireland. Wockhardt has a multi-ethnic workforce of over 6500 from 14 different nationalities.

**For more information, visit www.wockhardt.com
Corporate Relations Department**

For press enquiries about Wockhardt, please contact

›Daryl Suchitha
Associate Vice President - Corporate Relations
Wockhardt Limited
Wockhardt Towers, Bandra-Kurla Complex,
Bandra East, Mumbai 400 051, India.

Tel. : + 91 - 22 - 2653 4444 + 91 - 22 - 2653 4444
 Extension: 6303
Direct
Tel.: + 91 - 22 - 2659 6303 + 91 - 22 - 2659 6303
Fax: + 91 - 22 - 2653 4242
Email: daryls@wockhardt.com

Disclaimer:

The company would like to caution that any forward-looking statements or projections made by the company, including those made in the press release announcements, are subject to risks and uncertainties that may cause actual results to differ materially from those projected.